Gedea Biotech secures 1.3 MEuros (14 MSEK) to advance its antibiotic-free vaginal infection treatment pHyph towards market launch
Lund, Sweden, May 24, 2023: Gedea Biotech today announced that it has raised 1.3 MEuros (14 MSEK) for additional development activities of their product pHyph for antibiotic free treatment of vaginal infections. The funds will be used for: · An ongoing proof-of-concept study for the treatment of Vulvo Vaginal Candidiasis (VVC) with pHyph, partially financed by a recent grant from Swelife and Medtech4Health · Investigating how the vaginal microbiome changes during short- and long-term treatment with pHyph in patients with bacterial vaginosis · Preparation of an additional clinical